Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study

BACKGROUND: There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endophthalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-income countries. Moreover, findings from the existing trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangroongruangsri, Sermsiri, Chaikledkaew, Usa, Kumluang, Suthasinee, Wu, Olivia, Geue, Claudia, Ratanapakorn, Tanapat, Leelahavarong, Pattara, Ingsrisawang, Lily, Ruamviboonsuk, Paisan, Taweebanjongsin, Wongsiri, Choovuthayakorn, Janejit, Singalavanija, Apichart, Hanutsaha, Prut, Kulvichit, Kittisak, Ratanapojnard, Thitiporn, Wongsawad, Warapat, Teerawattananon, Yot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153972/
https://www.ncbi.nlm.nih.gov/pubmed/30069864
http://dx.doi.org/10.1007/s40261-018-0678-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153972/
https://www.ncbi.nlm.nih.gov/pubmed/30069864
http://dx.doi.org/10.1007/s40261-018-0678-5

Ejemplares similares